⚖️
Healthcare & Biotech Regulatory Redlines & Legal Risk 2011 - 2018

糖尿病药物的膀胱癌诉讼 (Takeda Actos):一款长期使用的糖尿病药,为什么会在多年后被追究责任?

上市后的长期安全性数据,决定了一款药能走多远

糖尿病药物的膀胱癌诉讼 (Takeda Actos):巅峰期日本大型制药企业的糖尿病治疗药物,曾在全球市场年销售额达数十亿美元级,是公司重要的收入来源之一,在多个国家被广泛处方;终局是因长期使用与膀胱癌风险的关联面临大量诉讼,法院作出巨额惩罚性赔偿判决,公司最终以二十亿美元级金额和解,产品销售与声誉长期受影响。

See the patterns
公开报道整理 待核查 Figures as of 2018 0 sources What do these mean?

How to read this bar

This bar states plainly what we know and what we have checked, so you can judge it yourself.

· Review status: “pending” means no editor has checked it against the sources yet; “checked” means key facts match the sources.

· Figures as of: the year the numbers are current to; later changes are out of scope.

· Sources: listed one by one at the bottom of the page. “Primary” means official filings, annual reports or regulator documents.

· Corrections: every change and its basis is published — nothing is edited silently.

Editorial policy → Editorial policy: the full inclusion rules, verification process, AI disclosure and correction promise.

No English translation for this case yet — showing the stored original.
Peak valuation

日本大型制药企业的糖尿病治疗药物,曾在全球市场年销售额达数十亿美元级,是公司重要的收入来源之一,在多个国家被广泛处方

Final cost

因长期使用与膀胱癌风险的关联面临大量诉讼,法院作出巨额惩罚性赔偿判决,公司最终以二十亿美元级金额和解,产品销售与声誉长期受影响

Attribution votes

5,906 votes cast

Community output

1 plans · 1 insights

Sponsored
把你亲历的失败写进来

投稿会先进入待审,通过后才进入公开目录和站点地图。

Root Causes Consensus Poll

Vote for the primary fatal error that caused this enterprise to collapse.

产品技术

长期安全性数据积累不足

获批时缺少长期用药的癌症风险数据,风险在上市后才显现

1,943 votes (33%)
外部合规

风险警示与沟通的及时性受质疑

标签更新与医生沟通被认为滞后,加重了法律责任

1,632 votes (28%)
资本财务

产品集中度带来财务风险

产品收入占比高,诉讼与和解对公司整体业绩影响放大

1,321 votes (22%)
战略

诉讼策略与陪审团预期

面对陪审团审判的不确定性,公司最终选择大规模和解切断风险

1,010 votes (17%)